vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $192.4M, roughly 1.0× Xometry, Inc.). Xometry, Inc. runs the higher net margin — -4.5% vs -14.6%, a 10.1% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 29.5%). Xometry, Inc. produced more free cash flow last quarter ($-5.9M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 25.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
AXSM vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $192.4M |
| Net Profit | $-28.6M | $-8.6M |
| Gross Margin | — | 39.1% |
| Operating Margin | -13.8% | -4.6% |
| Net Margin | -14.6% | -4.5% |
| Revenue YoY | 65.0% | 29.5% |
| Net Profit YoY | 61.9% | 12.7% |
| EPS (diluted) | $-0.55 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $192.4M | ||
| Q3 25 | $171.0M | $180.7M | ||
| Q2 25 | $150.0M | $162.5M | ||
| Q1 25 | $121.5M | $151.0M | ||
| Q4 24 | $118.8M | $148.5M | ||
| Q3 24 | $104.8M | $141.7M | ||
| Q2 24 | $87.2M | $132.6M | ||
| Q1 24 | $75.0M | $122.7M |
| Q4 25 | $-28.6M | $-8.6M | ||
| Q3 25 | $-47.2M | $-11.6M | ||
| Q2 25 | $-48.0M | $-26.4M | ||
| Q1 25 | $-59.4M | $-15.1M | ||
| Q4 24 | $-74.9M | $-9.9M | ||
| Q3 24 | $-64.6M | $-10.2M | ||
| Q2 24 | $-79.3M | $-13.7M | ||
| Q1 24 | $-68.4M | $-16.6M |
| Q4 25 | — | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | — | 40.1% | ||
| Q1 25 | — | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | — | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | -13.8% | -4.6% | ||
| Q3 25 | -27.0% | -6.1% | ||
| Q2 25 | -24.5% | -6.3% | ||
| Q1 25 | -46.9% | -10.2% | ||
| Q4 24 | -61.1% | -7.8% | ||
| Q3 24 | -59.8% | -8.1% | ||
| Q2 24 | -89.5% | -11.5% | ||
| Q1 24 | -89.7% | -14.6% |
| Q4 25 | -14.6% | -4.5% | ||
| Q3 25 | -27.6% | -6.4% | ||
| Q2 25 | -32.0% | -16.3% | ||
| Q1 25 | -48.9% | -10.0% | ||
| Q4 24 | -63.1% | -6.7% | ||
| Q3 24 | -61.7% | -7.2% | ||
| Q2 24 | -91.0% | -10.3% | ||
| Q1 24 | -91.1% | -13.5% |
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — | ||
| Q1 24 | $-1.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $219.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $275.6M |
| Total Assets | $689.8M | $703.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $219.1M | ||
| Q3 25 | $325.3M | $224.5M | ||
| Q2 25 | $303.0M | $225.8M | ||
| Q1 25 | $300.9M | $231.4M | ||
| Q4 24 | $315.4M | $239.8M | ||
| Q3 24 | $327.3M | $234.0M | ||
| Q2 24 | $315.7M | $240.9M | ||
| Q1 24 | $331.4M | $253.8M |
| Q4 25 | $88.3M | $275.6M | ||
| Q3 25 | $73.7M | $272.0M | ||
| Q2 25 | $73.1M | $270.4M | ||
| Q1 25 | $53.2M | $309.9M | ||
| Q4 24 | $57.0M | $314.5M | ||
| Q3 24 | $92.9M | $315.2M | ||
| Q2 24 | $102.9M | $315.8M | ||
| Q1 24 | $144.0M | $320.4M |
| Q4 25 | $689.8M | $703.7M | ||
| Q3 25 | $669.3M | $698.9M | ||
| Q2 25 | $639.8M | $687.0M | ||
| Q1 25 | $596.7M | $690.1M | ||
| Q4 24 | $568.5M | $680.1M | ||
| Q3 24 | $561.5M | $678.2M | ||
| Q2 24 | $548.2M | $678.6M | ||
| Q1 24 | $545.7M | $692.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $4.4M |
| Free Cash FlowOCF − Capex | $-18.7M | $-5.9M |
| FCF MarginFCF / Revenue | -9.6% | -3.0% |
| Capex IntensityCapex / Revenue | 0.0% | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $4.4M | ||
| Q3 25 | $1.0M | $5.8M | ||
| Q2 25 | $-32.4M | $-427.0K | ||
| Q1 25 | $-43.4M | $-3.7M | ||
| Q4 24 | $-26.2M | $9.1M | ||
| Q3 24 | $-18.6M | $-3.6M | ||
| Q2 24 | $-30.1M | $-9.1M | ||
| Q1 24 | $-53.5M | $-11.7M |
| Q4 25 | $-18.7M | $-5.9M | ||
| Q3 25 | $988.0K | $-1.7M | ||
| Q2 25 | $-32.4M | $-7.4M | ||
| Q1 25 | $-43.7M | $-9.2M | ||
| Q4 24 | $-26.2M | $4.5M | ||
| Q3 24 | $-18.7M | $-8.4M | ||
| Q2 24 | $-30.2M | $-13.5M | ||
| Q1 24 | $-53.6M | $-16.1M |
| Q4 25 | -9.6% | -3.0% | ||
| Q3 25 | 0.6% | -0.9% | ||
| Q2 25 | -21.6% | -4.5% | ||
| Q1 25 | -36.0% | -6.1% | ||
| Q4 24 | -22.1% | 3.1% | ||
| Q3 24 | -17.9% | -6.0% | ||
| Q2 24 | -34.6% | -10.2% | ||
| Q1 24 | -71.4% | -13.1% |
| Q4 25 | 0.0% | 5.3% | ||
| Q3 25 | 0.0% | 4.1% | ||
| Q2 25 | 0.0% | 4.3% | ||
| Q1 25 | 0.3% | 3.6% | ||
| Q4 24 | 0.0% | 3.1% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 0.1% | 3.3% | ||
| Q1 24 | 0.1% | 3.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
